Elevate your clinical studies through a validated
methodology coupled with a specialized machine
learning model. Our DOORs solution can help you identify optimal companion
diagnostics, novel biomarker panels for your
research, or ribosome-targeting drug candidates.
DOORs is a pioneering approach designed for the identification and data mining of a hidden layer of the transcriptome, specifically targeting 3'P RNA fragments.
The DOORs platform enables detection and quantification of elusive 3'-phosphorylated (3'P) RNA fragments. It is based on two powerful technologies: Dart-RNA and P-ROC. The first innovation enables selective capture and quantification of nuclease-cleaved RNA fragments, while P-ROC, as a machine learning-driven tool, enables interpretation of the identified hits. After omic screening with Dart-RNA and P-ROC, we validate the marker leads with a novel targeted qPCR method. Finally, we can screen fragments bound to ribosomes able to modulate protein synthesis (RNA-drug modulators).
From the same workflow DOORs enables:
- Identification of potential disease markers or drug leads through highly specific omics and targeted fragment assays on a single sequence
- Investigation of potential companion diagnostics for targeted drug treatments
- Exploration of new types of ssRNA drug action on the ribosome body
The methodology is applicable to various diseases and biological models.
Scientific foundation:
- A breakthrough, novel enzyme developed by Immagina underpins the platform
- Our proprietary technology protected by three issued patents on novel methods and RNA sequences. Validated lead candidates have already been identified using this technology.
- A powerful and fully operational AI pipeline that is already driving discovery for potential clinical applications.
- Successful completion of two proof-of-concept studies demonstrating real-world applicability.
DOORS strength
FAST assay development
FLEXIBLE OUTPUTS OMIC and qPCR endpoints
MULTIPLE markers detections
ALL INPUTS both solid or liquid biopsies
HARDWARE EASY equipment agnostic & fit to multiple readounts platforms
CLINICAL DATABASE AVAILABLE on Melanoma, cSCC and SMA
Options for ad-hoc services collaborations or co-development
| Project identifier | Intended-use | Discovery | Validation | Design & development | Performance evaluation | IVD | Rights |
|---|---|---|---|---|---|---|---|
| qPCR panel for skin cancer | N.D | IMMAGINA | |||||
| qPCR panel for SMA | N.D | IMMAGINA | |||||
| OMIC chart and database skin cancer | N.D | IMMAGINA |
| Project identifier | Intended-use | Discovery | Pre-clinical | Phase I | Phase II | Phase III | Rights |
|---|---|---|---|---|---|---|---|
| RNA-drug suppressor | 3'P Ribosome Modulator - protein sinthesis suppressor drug or adiuvant | IMMAGINA | |||||
| RNA-drug activator | 3'P Ribosome Modulator - protein sinthesis activator drug or adiuvant | IMMAGINA |
By harnessing the potential of these methods, IMMAGINA anticipates substantial success with DOORs